It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Rational Pharmacotherapy in CardiologySafety of amiodarone usage in patients with Wolff-Parkinson-White syndrome and atrial fibrillation

Safety of amiodarone usage in patients with Wolff-Parkinson-White syndrome and atrial fibrillation

D.A. Kuzhel1,2*, G.V. Matyushin1, E.A. Savchenko1

1 Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky. Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia

2 Krasnoyarsk Territory Hospital N2. Karla Marxa ul. 43, Krasnoyarsk, 660097 Russia

Amiodarone is one of the basic antiarrhytmic drugs for atrial fibrillation treatment. However application of amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome can induce ventricular fibrillation. Amiodarone usage in these patients should be accompanied by readiness for performance of resuscitation. This is confirmed by clinical case presentation.

Key words: amiodarone, atrial fibrillation, Wolff-Parkinson-White syndrome, ventricular fibrillation.

Rational Pharmacother. Card. 2010;6(3):359-362

* Corresponding author: ofdkkb2@4mail.ru


Download free full text (PDF)

© 2007 — 2014 «Rational Pharmacotherapy in Cardiology»
«Stolichnaya Izdatelskaya Kompaniya»

ISSN 1819-6446(Print) ISSN 2225-3653 (Online)